Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References 2 Further reading

Lamivudine/tenofovir

●한국어 Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia (Redirected from Lamivudine/tenofovir disoproxil)

This article relies excessively on referencestoprimary sources. Please improve this article by adding secondary or tertiary sources.
Find sources: "Lamivudine/tenofovir" – news · newspapers · books · scholar · JSTOR (March 2020) (Learn how and when to remove this message)

Lamivudine/tenofovir
Combination of

Lamivudine	Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil	Nucleotide reverse transcriptase inhibitor
Clinical data
Trade names	Cimduo, Temixys
AHFS/Drugs.com	Monograph
MedlinePlus	a618039
License data	US DailyMed: Cimduo
Routes of administration	By mouth
ATC code	J05AR12 (WHO)
Legal status
Legal status	US: ℞-only^[1]^[2]
Identifiers
KEGG	D11395

Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).^[1]^[3] It contains lamivudine and tenofovir disoproxil.^[1] It is taken by mouth.^[1]

Lamivudine/tenofovir was approved for medical use in the United States in February 2018.^[1]^[4]

References[edit]

^ ^a ^b ^c ^d ^e "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Archived from the original on 15 February 2020. Retrieved 26 March 2020.

^ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Archived from the original on 14 February 2022. Retrieved 13 February 2022.

^ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Archived from the original on 26 March 2020. Retrieved 26 March 2020.

Entry/fusion inhibitors
(Discovery and development)

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Protease Inhibitors (PI)
(Discovery and development)

1^st generation

2^nd generation

Non-nucleoside (NNRTI)
(Discovery and development)

1^st generation

2^nd generation

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide KP-1461^† Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

^‡Withdrawn from market

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.